Guided P2Y12 inhibitor therapy after percutaneous coronary intervention

被引：0
|
作者：
Sibbing, Dirk [1 ,2 ,3 ]
Kastrati, Adnan [3 ,4 ]
机构：
[1] Privatklin Lauterbacher Muhle Ostersee, Iffeldorf, Germany
[2] Ludwig Maximilians Univ Munchen, Klinikum Univ Munchen, Dept Cardiol, D-80636 Munich, Germany
[3] German Ctr Cardiovasc Res DZHK, Partner Site Munich Heart Alliance, Munich, Germany
[4] Tech Univ Munich, Dept Cardiol, Deutsch Herzzentrum Munchen, D-80636 Munich, Germany
来源：
LANCET | 2021年 / 397卷 / 10283期
关键词：
ANTIPLATELET TREATMENT; CLOPIDOGREL; STANDARD;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1423 / 1425
页数：4
相关论文
共 50 条
  • [1] Genotype-Guided P2Y12 Inhibitor Therapy After Percutaneous Coronary Intervention: A Bayesian Analysis
    Parcha, Vibhu
    Heindl, Brittain F.
    Li, Peng
    Kalra, Rajat
    Limdi, Nita A.
    Pereira, Naveen L.
    Arora, Garima
    Arora, Pankaj
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2021, 14 (06): : 731 - 739
  • [2] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention
    Zhou, Xuan
    Angiolillo, Dominick J.
    Ortega-Paz, Luis
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2022, 9 (10)
  • [3] GENOTYPE-GUIDED P2Y12 INHIBITOR THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION- A BAYESIAN ANALYSIS
    Parcha, Vibhu
    Heindl, Brittain
    Li, Peng
    Kalra, Rajat
    Limdi, Nita
    Pereira, Naveen
    Arora, Garima
    Arora, Pankaj
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (18) : 158 - 158
  • [4] P2Y12 Inhibitor or Aspirin Following Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
    Ando, Giuseppe
    De Santis, Giulia Azzurra
    Greco, Antonio
    Pistelli, Lorenzo
    Francaviglia, Bruno
    Capodanno, Davide
    De Caterina, Raffaele
    Capranzano, Piera
    JACC-CARDIOVASCULAR INTERVENTIONS, 2022, 15 (22) : 2239 - 2249
  • [5] P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
    McCaw, Zachary R.
    Wei, Lee-Jen
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2019, 322 (16): : 1607 - 1607
  • [6] P2Y12 INHIBITOR MONOTHERAPY OR DUAL ANTIPLATELET THERAPY AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH HYPERTENSION
    Pil-Sang, Song
    Jin-Ok, Jeong
    JOURNAL OF HYPERTENSION, 2023, 41 : E178 - E178
  • [7] The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention
    Luo, Liman
    Fu, Menglu
    Li, Yuanyuan
    Chen, Zhihui
    Yu, Jing
    Luo, Jinlan
    Hu, Shuiqing
    Tu, Ling
    Xu, Xizhen
    CLINICAL CARDIOLOGY, 2020, 43 (03) : 235 - 241
  • [8] P2Y12 Inhibitor Monotherapy after Percutaneous Coronary Intervention: Is It Safe to Abandon Aspirin?
    Feng, Wen-Han
    Hsieh, I-Chang
    Li, Yi-Heng
    ACTA CARDIOLOGICA SINICA, 2021, 37 (01) : 1 - 8
  • [9] P2Y12 blocker monotherapy after percutaneous coronary intervention
    F. W. A. Verheugt
    P. Damman
    S. A. J. Damen
    J. J. Wykrzykowska
    E. C. I. Woelders
    R. -J. M. van Geuns
    Netherlands Heart Journal, 2021, 29 : 566 - 576
  • [10] Selection of P2Y12 Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome
    Tantry, Udaya S.
    Navarese, Eliano P.
    Myat, Aung
    Gurbel, Paul A.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2018, 60 (4-5) : 460 - 470
12345